Tony Ng is the Richard Dimbleby Professor of Cancer Research, King’s College London and Professor of Molecular Oncology at University College London (UCL) Cancer Institute. He obtained his Medical Degree from University of Aberdeen, Scotland and PhD in Immunology from Medical College of St. Bartholomew’s Hospital, London. He has a mix of training/expertise in medicine, immunology, cancer cell biology, biochemistry, optical imaging and cell biophysics. Because of this mixed clinical/scientific background, he has adopted a multidisciplinary approach to understand cancer metastasis.
His team is one of the few research groups in the UK & internationally, which can bridge the gap between Physics, Biology and Medicine, particularly in the field of translational cancer research. Professor Ng is currently the Principal Investigator and Coordinator for the KCL-UCL Comprehensive Cancer Imaging Centre. He is also the Joint lead for The CRUK Lung Cancer Centre of Excellence Biomarkers theme (http://www.cruklungcentre.org/Research/Biomarkers). In addition, he leads the Tumour Immunology imaging project within the Breast Cancer Now Unit at KCL. The central driver for his engagements in these translational centres is to deliver a coherent & translationally oriented imaging-genomic-protein network combination approach, that his team has pioneered in developing over the recent years, to individualise cancer treatment. Most recently he has also expanded his imaging repertoire to the development of radionuclide imaging tracers against targeted molecules.
For his multidisciplinary research contribution in cancer he was elected to the Academy of Medical Sciences as a Fellow (FMedSci )in 2013. In this conference, he will share his thoughts on the use of the heterogeneous expression of exosomal HER receptors as well as their dimers as exploratory predictive markers for the use of ErbB/HER therapeutics, in conjunction with a novel HER3 radionuclide-based imaging tracer. The translational vision of combining whole body immuno-PET imaging of HER and exosomal receptor rewiring information, in correct stratification of patient treatment, will be discussed.